Treatable traits: toward precision medicine of chronic airway diseases

By Alvar Agusti, E. Bel, M. Thomas, C. Vogelmeier, G. Brusselle, S. Holgate, M. Humbert, P. Jones, P. Gibson, Jorgen Vestbo and 2 more. European Respiratory Journal, 2016

1,002 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/635750b4a2b03b1ec212cba2bbb96b567a2f7acb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. J. Wedzicha
2. D. Parums

In Pulmonary and Respiratory Medicine

1. A. Anzueto
2. Bartolome Celli
3. J. Wedzicha
4. R. Stockley
5. D. Parums
6. P. Barnes

Citations in the corpus

• Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary (2023, positive): “GOLD 2023 continues to recommend that follow-up treatment be based on two key treatable traits (TTs) (91): dyspnea and occurrence of exacerbations (Figure 4).”
• Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes (2021, positive): “Assess not only symptom control and lung function but also the individual ’ s modi fi able risk factors and comorbidities (also called “ treatable traits ” ) 17 and patient/parent goals and preferences.”